- Worldwide & US trial landscapes
- Treatments being studied – the rationale for these drugs and how far along they are in clinical studies
- US trials and site locations
- A perspective from an ICU doctor with anecdotal drug/critical care experience treating COVID-19 patients
Dr. Jeff Scott is a fellow specializing in Pulmonary and Critical Care Medicine at the University of California Irvine. He graduated from medical school from Saint Louis University in 2012 and completed his Internal Medicine training at Highland Hospital in Oakland, CA. Dr. Scott is board-certified in Internal Medicine, Pulmonary Medicine, and will be taking the Critical Care board exam this autumn. Upon completion of his fellowship in June, he will be returning to the San Francisco Bay area to work as a full-time clinician in both Pulmonary and Critical Care Medicine.
Dr. Ly Nguyen-Jatkoe is the Commercial Strategy Director at Informa. Ly’s experience includes market research in oncology, autoimmune conditions, and infectious diseases and she is the former VP of Disease Analysis and Strategy at Informa Pharma Intelligence. Ly has a PhD in Physiology and Pharmacology from the University of New South Wales in Sydney, Australia and did her postdoctoral research in R&D at Johnson & Johnson.
Astrid Kurniawan is a Senior Market Access Analyst at Informa. Astrid has deep pharmaceutical and healthcare consulting experience in both the private and public sectors for global major markets and developing countries. Her research and analysis expertise focus on market access trends in immunology and inflammation indications, multiple sclerosis, asthma, and COPD, along with several oncology indications. She has authored several white papers and is a much sought after speaker on various market access topics.